Incretin & Metabolic Receptor Agonists
Retatrutide
Also known as LY3437943
Late-stage human trialsInvestigational
Last reviewed: 2026-11-19
History
Eli Lilly developed LY3437943; early clinical reports appeared in 2022 and phase 2 results in 2023.
Key sources
Identity and editorial screen completed November 19, 2026. Previously checked primary references retained; this is not an exhaustive clinical review.
Related compounds
- Semaglutide
Same scientific class · A 31-amino-acid chain. · FDA-approved for specific indications
- Tirzepatide
Same scientific class · A 39-amino-acid chain. · FDA-approved for specific indications